Victor J. Dzau Professor of Medicine, Brigham and Women's Hospital
Cardiology
Dr. Marc A. Pfeffer, MD
|
|
Give Review
Marc A. Pfeffer, MD practices Cardiology. He went to University of Oklahoma College of Medicine. He over the years received 4 awards: "America's Top Doctors", "Boston Magazine", "Fellow (FACC)" and "Super Doctor". Marc Pfeffer is also published. He has 102 publications published. The lastest publication: "Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Ant...' He is registered with Medicare and accepts Medicare payments.
Publications
- B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients.
- Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, Heart failure, or both after myocardial infarction.
- Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
- Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Tr...
- Baseline distribution of participants with depression and impaired quality of life in the treatment of preserved cardiac function Heart failure with an aldosterone ant...
- Site selection for Heart failure clinical trials in the USA.
- Exercise training as therapy for Heart failure: current status and future directions.
- Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic Heart failure across the spectrum of ...
- Prognostic importance of temporal changes in resting Heart rate in Heart failure patients: an analysis of the CHARM program.
- Guidelines and guidance in lipid modification.
- Searching for treatments of Heart failure with preserved ejection fraction: matching the data to the question.
- Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial.
- Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction: Findings From the Echocardiographic Study of the Treatment of Preserved...
- Left Ventricular Size, Mass, and Shape: Is the Sum Greater Than the Parts?
- Enhancing Trial Integrity by Protecting the Independence of Data Monitoring Committees in Clinical Trials.
- Heart failure with preserved ejection fraction: a forest of a variety of trees.
- Influence of Prior Heart Failure Hospitalization on Cardiovascular Events in Patients with Reduced and Preserved Ejection Fraction.
- Treatment of diabetes mellitus: the urgent need for multifactorial interventions.
- Spironolactone for Heart failure with preserved ejection fraction.
- Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction: A VALIANT Study (Valsartan In Acute Myocardial Infa...
- Developing Therapies for Heart Failure With Preserved Ejection Fraction: Current State and Future Directions.
- The impact of kidney function on outcomes following high risk Myocardial infarction: findings from 27â610 patients.
- Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease.
- Survival with Cardiac-Resynchronization Therapy in Mild Heart Failure.
- Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
- Prognosis and response to therapy of first inpatient and outpatient Heart failure event in a Heart failure clinical trial: MADIT-CRT.
- Assessment of Myocardial viability and left ventricular function in patients supported by a left ventricular assist device.
- Emerging clinical challenges in the use of statins.
- PRAISE (Prospective Randomized Amlodipine Survival Evaluation) and Criticism.
- Right ventricular function, Pulmonary pressure estimation, and clinical outcomes in cardiac resynchronization therapy.
- Cancer in cardiovascular drug trials and vice versa: a personal perspective.
- Acute Effects of Withdrawal of Cardiac Resynchronization Therapy on Left and Right Ventricular Function, Dyssynchrony, and Contractile Function in Patients With New Yo...
- Effects of cardiac resynchronization therapy on left ventricular mass and wall thickness in mild Heart failure patients in MADIT-CRT.
- Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
- Moving beyond our comfort zone.
- Heart failure: The many faces of Heart failure with preserved ejection fraction.
- Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of Acute lung injury.
- Mechanisms and predictors of mitral regurgitation after high-risk Myocardial infarction.
- Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients with Stable Coronary Disease.
- Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolacton...
- Days alive and out of hospital and the patient journey in patients with Heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Morta...
- Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney Disease, and anemia: An analysis of the Trial to Reduc...
- Cardiac structure and function, remodeling, and clinical outcomes among patients with diabetes after Myocardial infarction complicated by left ventricular systolic dys...
- Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following Myocardial infarction and the influence of ...
- Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification...
- Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD.
- Access to safety data--stockholders versus prescribers.
- Circumstances and outcomes of sudden unexpected death in patients with high-risk Myocardial infarction: implications for prevention.
- Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of Heart failure after high-risk myocardial infarc...
- Dyssynchrony, Contractile Function, and Response to Cardiac Resynchronization Therapy.
- Homocysteine-lowering and cardiovascular Disease outcomes in kidney transplant recipients: primary results from the folic Acid for vascular outcome reduction in transp...
- HMG CoA Reduction in Patients with Average Cholesterol Concentrations.
- Functionally competent cardiac stem cells can be isolated from endoMyocardial biopsies of patients with advanced cardiomyopathies.
- Risk of all-cause mortality, recurrent myocardial infarction, and Heart failure hospitalization associated with smoking status following myocardial infarction with lef...
- Composite outcomes: weighting component events according to severity assisted interpretation but reduced statistical power.
- ACCORD(ing) to a trialist.
- Acute decline in renal function, inflammation, and cardiovascular risk after an Acute coronary syndrome.
- Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial In...
- Dual renin-angiotensin system blockade and kidney Disease.
- Dual renin-angiotensin system blockade in Heart failure.
- Red blood cell distribution width and mortality risk in a community-based prospective cohort.
- Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
- Left Atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study.
- Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in ...
- Leapfrogging data: no shortcuts for safety or efficacy information.
- Anemia treatment in chronic kidney Disease: shifting uncertainty.
- Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic...
- Racial analysis of patients with myocardial infarction complicated by Heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both.
- Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with Atrial fibrillation according to stroke risk: the Atrial fibrillatio...
- High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
- Comparison of renal function and cardiovascular risk following Acute myocardial infarction in patients with and without diabetes mellitus.
- Estimated glomerular filtration rate, inflammation, and cardiovascular events after an Acute coronary syndrome.
- Usefulness of right ventricular fractional area change to predict death, Heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study).
- Critical missing data on erythropoiesis-stimulating agents in CKD: first beat placebo.
- Association between ADAMTS1 matrix metalloproteinase gene variation, Coronary heart disease, and benefit of statin therapy.
- Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and Coronary heart disease in 2 prospective trials: the CARE and WOSCOPS...
- Aortic diameter, wall stiffness, and wave reflection in systolic hypertension.
- Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk Myocardial infarction.
- The relationship between renal function and cardiac structure, function, and prognosis after Myocardial infarction: the VALIANT Echo Study.
- Left ventricular end-diastolic pressure and risk of subsequent heart failure in patients following an Acute myocardial infarction.
- The CHARM program: study design leads to findings of clinical and public health importance.
- Augmentation index and central Aortic stiffness in middle-aged to elderly individuals.
- Long-term outcomes of left bundle branch block in high-risk survivors of Acute myocardial infarction: the VALIANT experience.
- Blood pressure in Heart failure: a love-hate relationship.
- Kidney Disease and cardiovascular risk.
- Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, Heart failure, or both after myocardial inf...
- Variable impact of combining fatal and nonfatal end points in Heart failure trials.
- Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation.
- Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after Myocardial infarction.
- Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial.
- Prevention of Atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mor...
- The charisma of subgroups and the subgroups of CHARISMA.
- The association of the Heart failure score with mortality and Heart failure hospitalizations in elderly patients: insights from the Mode Selection Trial (MOST).
- On expectations: address to the ochsner clinic graduating residents and fellows on june 6, 2006.
- Effect of pravastatin on rate of kidney function loss in people with or at risk for Coronary disease.
- Changes in ventricular size and function in patients treated with valsartan, captopril, or both after Myocardial infarction.
- Evaluation and management of patients with uncontrolled systolic Hypertension: is another new paradigm really needed?
- Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney Disease.
- Uncertainty in the treatment of anemia in chronic kidney Disease.
- Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Ant...
- Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with Heart failure with preserved ejection fraction.
Schools
University Of Oklahoma College Of Medicine
Peter Bent Brigham Hospital
Procedures Preformed
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac Myocardial Perfusion Imaging
- Cardioverter-Defibrillator or Pacemaker Insertion, Removal or Repair
Conditions Treated
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Valve Disease
- Arrhythmias (incl. Atrial Fibrillation)
- View All
Doctors Specialties
- Cardiology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- America's Top Doctors
- Boston Magazine
- Fellow (FACC)
- Super Doctor
Education
-
Brigham and Women's Hospital -
University of Oklahoma College of Medicine
Hospital
-
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1598703860 | |
| NPPES Provider LastName | PFEFFER | |
| NPPES Provider FirstName | MARC | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 81.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1598703860 |
| Last Name Of The Provider | PFEFFER |
| First Name Of The Provider | MARC |
| View All |
Similar Doctors
|
|
Dr. Klaus Lindpaintner, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ron Blankstein, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Christopher U. Meduri, MD |
|
|
Dr. Richard T. Lee, MD |
|
|
Dr. Harold E. Lindsey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph A. Vita, MD |